Blog | HemaCare

Developing Antibody Drugs Against B-cells

Jan 11, 2016 1:00:44 PM / by Daisy Goodrich posted in Cancer, clinical trial, obinutuzumab, Basic Research, Immunotherapy (Immunology)


The success of rituximab as an antibody drug targeting B-cells has led to the development of obinutuzumab – a similar, third-generation drug

Chronic lymphocytic leukemia (CLL) is a B-cell disease that is currently incurable. Combining targeted drugs has improved overall survival. However, not all patients benefit, because B-cells can harness any of several mechanisms to gain unrestricted proliferative capacity (see here).

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts